🔎 Trials Near Me

Akèy › Kansè poumon › Ohio › Parma

Etid klinik pou Kansè poumon nan Parma, OH

5 etid pou Kansè poumon ap chèche patisipan nan sit nan ak bò kote Parma (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Ap rekriteFaz 3
  • Cleveland Clinic Cancer Center Independence, Independence · 5 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04267848

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Ap rekriteFaz 3
  • UH Seidman Cancer Center at UH Avon Health Center, Avon · 17 mi lwen
Laj 70 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06096844

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Ap rekriteFaz 3
  • UH Seidman Cancer Center at Southwest General Hospital, Middleburg Heights · 6 mi lwen
  • UH Seidman Cancer Center at UH Avon Health Center, Avon · 17 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT04181060

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Ap rekriteFaz 3
  • University Hospitals Seidman Cancer Center at UH Avon Health Center, Avon · 17 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06758401

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Ap rekriteFaz 3
  • UH Seidman Cancer Center at UH Avon Health Center, Avon · 17 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05624996

Etid Kansè poumon nan lòt vil

Lòt etid nan Parma

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.